FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910338537> ?p ?o ?g. }

• W2910338537 endingPage "2123" @default.
• W2910338537 startingPage "2123" @default.
• W2910338537 abstract "Abstract Introduction Nicotinamide-expanded cord blood (NiCord) is a promising alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-matched donor is unavailable. A phase 1/2 trial with standalone NiCord HCT showed rapid neutrophil engraftment (median 11 days) and platelet engraftment (median 34 days). However, successful CD4+ immune reconstitution (IR) has shown to be crucial for infectious and relapse control associated with favorable survival (Admiraal JACI 2017). We performed unique in-depth immune monitoring to evaluate and compare the recovery of immune subsets after NiCord and conventional HCT. Methods In the phase1/2 multicenter trial, patients (n=36) with hematologic malignancies received NiCord-HCT after myeloablative (MA) conditioning without antithymocyte globulin (ATG). Immune monitoring was performed (harmonized sampling, handling and analyses in a central lab) in a random subgroup. The primary endpoint was probability of achieving CD4+ IR (>50*106/L within 100 days). Secondary endpoints were subset recovery over time of B-cells, CD4+ and CD8+ T-cells, natural killer (NK), monocytes, and dendritic cells (DC), during 7-365 days after HCT. In addition, TREC analyses are pending and will be available at the meeting. Data were compared with IR in cohorts of adolescent and young adult (AYA) patients at the UMC Utrecht receiving either unmanipulated cord blood transplantation (unCBT) or T-repleted unrelated bone marrow transplantation (BMT) for hematological malignancy after MA conditioning without ATG. Linear-mixed effects modelling in LOESS-regression curves and two-sided log-rank test for univariate comparisons in cumulative incidence plots were used. Results 24 NiCord recipients (median 41.5; 13.4-61.7 yrs) had blood samples available for in-depth early immune monitoring. NiCord cell dose consisted of median 6.4*106 CD34+/kg, and 2.3*106 CD3+T-cells/kg of the co-infused negative fraction (following CD133+-selection). 91% of patients achieved successful early CD4+ IR after NiCord (Fig 1). When comparing the NiCord with 27 unCBT (median age 15.4; range 12.2-22.1 yrs) and 20 BMT (median age 14.3; range 12.1-19.7 yrs), no difference in probability of early CD4+ IR was noted (p=0.76: Fig 1). Overall T-cell reconstitution was similar; CD3+ (p=0.99), CD4+ (p=0.71), CD8+ (p=0.08), although effector and central memory CD4+ and CD8+ T-cells, Tregs, gamma-delta T-cells, Th2, and Th17 recovered somewhat faster after NiCord. Recovery of conventional- (p=0.41) and plasmacytoid DCs (p=0.52) was similar as well. Overall reconstitution of NK-cells (p<0.001); especially naïve NK-cells, monocytes (p<0.001); mostly classical, and B-cells (p=0.026) was faster after HCT with NiCord, compared to unCBT and BMT cohorts (Fig 2). In B-cell recovery, strikingly faster early recovery of follicular B-cells (p=0.04), memory B-cells (p=0.003), and plasma cells (p=0.003) was observed in NiCord recipients. Conclusions In-depth immune monitoring reveals rapid and robust immune reconstitution in NiCord recipients, with high early CD4+ IR probability, and comparable recovery of T-cell-, NK-cell-, monocyte-, and DC-subsets to AYA controls receiving unCBT and BMT. Interestingly, B-cell recovery consisted of markedly higher follicular B-cell, memory B-cell, and plasma cell levels in NiCord recipients. Next to higher B-cell recovery, monocyte and NK-cells also recovered faster after NiCord transplantation, despite the younger age of the AYA cohort (expected to reconstituted faster). This may be explained by the higher stem cell dose and higher proliferative capacity of the NiCord- expanded product. Optimal comparison of IR in NiCord vs. unCBT in a randomized phase 3 trial is underway. Disclosures Horwitz: Gamida Cell: Research Funding. Jagasia:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees. Wagner:Magenta Therapeutics: Consultancy, Research Funding; Novartis: Research Funding. Cilloni:Janssen: Membership on an entity's Board of Directors or advisory committees; celgene: Membership on an entity's Board of Directors or advisory committees. Nierkens:Gamida: Research Funding." @default.
• W2910338537 created "2019-01-25" @default.
• W2910338537 creator A5001390394 @default.
• W2910338537 creator A5013177563 @default.
• W2910338537 creator A5018922885 @default.
• W2910338537 creator A5025675788 @default.
• W2910338537 creator A5049744314 @default.
• W2910338537 creator A5052934298 @default.
• W2910338537 creator A5070008988 @default.
• W2910338537 creator A5086290087 @default.
• W2910338537 creator A5087156523 @default.
• W2910338537 creator A5090889745 @default.
• W2910338537 date "2018-11-29" @default.
• W2910338537 modified "2023-10-16" @default.
• W2910338537 title "Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation" @default.
• W2910338537 doi "https://doi.org/10.1182/blood-2018-99-116700" @default.
• W2910338537 hasPublicationYear "2018" @default.
• W2910338537 type Work @default.
• W2910338537 sameAs 2910338537 @default.
• W2910338537 citedByCount "0" @default.
• W2910338537 crossrefType "journal-article" @default.
• W2910338537 hasAuthorship W2910338537A5001390394 @default.
• W2910338537 hasAuthorship W2910338537A5013177563 @default.
• W2910338537 hasAuthorship W2910338537A5018922885 @default.
• W2910338537 hasAuthorship W2910338537A5025675788 @default.
• W2910338537 hasAuthorship W2910338537A5049744314 @default.
• W2910338537 hasAuthorship W2910338537A5052934298 @default.
• W2910338537 hasAuthorship W2910338537A5070008988 @default.
• W2910338537 hasAuthorship W2910338537A5086290087 @default.
• W2910338537 hasAuthorship W2910338537A5087156523 @default.
• W2910338537 hasAuthorship W2910338537A5090889745 @default.
• W2910338537 hasBestOaLocation W29103385371 @default.
• W2910338537 hasConcept C126322002 @default.
• W2910338537 hasConcept C167672396 @default.
• W2910338537 hasConcept C203014093 @default.
• W2910338537 hasConcept C2777408962 @default.
• W2910338537 hasConcept C2780007613 @default.
• W2910338537 hasConcept C2780914630 @default.
• W2910338537 hasConcept C2908824208 @default.
• W2910338537 hasConcept C2911091166 @default.
• W2910338537 hasConcept C71924100 @default.
• W2910338537 hasConcept C88879693 @default.
• W2910338537 hasConcept C8891405 @default.
• W2910338537 hasConcept C90924648 @default.
• W2910338537 hasConceptScore W2910338537C126322002 @default.
• W2910338537 hasConceptScore W2910338537C167672396 @default.
• W2910338537 hasConceptScore W2910338537C203014093 @default.
• W2910338537 hasConceptScore W2910338537C2777408962 @default.
• W2910338537 hasConceptScore W2910338537C2780007613 @default.
• W2910338537 hasConceptScore W2910338537C2780914630 @default.
• W2910338537 hasConceptScore W2910338537C2908824208 @default.
• W2910338537 hasConceptScore W2910338537C2911091166 @default.
• W2910338537 hasConceptScore W2910338537C71924100 @default.
• W2910338537 hasConceptScore W2910338537C88879693 @default.
• W2910338537 hasConceptScore W2910338537C8891405 @default.
• W2910338537 hasConceptScore W2910338537C90924648 @default.
• W2910338537 hasIssue "Supplement 1" @default.
• W2910338537 hasLocation W29103385371 @default.
• W2910338537 hasOpenAccess W2910338537 @default.
• W2910338537 hasPrimaryLocation W29103385371 @default.
• W2910338537 hasRelatedWork W2052913478 @default.
• W2910338537 hasRelatedWork W2187326722 @default.
• W2910338537 hasRelatedWork W2359804617 @default.
• W2910338537 hasRelatedWork W2365848850 @default.
• W2910338537 hasRelatedWork W2392641532 @default.
• W2910338537 hasRelatedWork W2442220036 @default.
• W2910338537 hasRelatedWork W2591816604 @default.
• W2910338537 hasRelatedWork W265735815 @default.
• W2910338537 hasRelatedWork W4247148241 @default.
• W2910338537 hasRelatedWork W2114487924 @default.
• W2910338537 hasVolume "132" @default.
• W2910338537 isParatext "false" @default.
• W2910338537 isRetracted "false" @default.
• W2910338537 magId "2910338537" @default.
• W2910338537 workType "article" @default.